Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XRD-0394 with palliative radiotherapy in advanced cancer
NCT05002140Phase 1Completed
- Sponsor
- XRad Therapeutics
- Start
- Aug 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of xrd-0394 in solid tumor (4 arms), sponsored by XRad Therapeutics. Primary endpoints: Number of subjects with at least 1 dose-limiting toxicity and Number of subjects experiencing treatment-emergent adverse events. Started Aug 2021; status: completed.
02
Drugs
xrd-0394
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05002140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05002140.